Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia.
Under the agreement Royalty Pharma will provide $50 million upfront to Merck to support ongoing development of MK-8189. Following Merck’s decision to proceed with Phase 3, Royalty Pharma has the option to provide an additional $375 million to co-fund the pivotal clinical development program. Royalty Pharma will be eligible for milestone payments associated with certain regulatory approvals for MK-8189 as well as royalties on annual worldwide sales of any approved product.
https://finance.yahoo.com/news/royalty-pharma-announces-r-d-110000586.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.